MA39390A1 - Thérapie génique pour le traitement de la rétinite pigmentaire - Google Patents

Thérapie génique pour le traitement de la rétinite pigmentaire

Info

Publication number
MA39390A1
MA39390A1 MA39390A MA39390A MA39390A1 MA 39390 A1 MA39390 A1 MA 39390A1 MA 39390 A MA39390 A MA 39390A MA 39390 A MA39390 A MA 39390A MA 39390 A1 MA39390 A1 MA 39390A1
Authority
MA
Morocco
Prior art keywords
treatment
retinitis pigmentosa
gene therapy
particles
mir
Prior art date
Application number
MA39390A
Other languages
English (en)
Other versions
MA39390B2 (fr
Inventor
Catherine Oriordan
Matthew Adamowicz
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA39390A1 publication Critical patent/MA39390A1/fr
Publication of MA39390B2 publication Critical patent/MA39390B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour le traitement de la rétinite pigmentaire au moyen de particules d'aav codant mir -708. Dans un aspect de l'invention, des particules virales sont administrées dans l'œil d'un sujet humain, par exemple, par injection sous-rétinienne. Des particules virales comprenant des capsides d'aav5 ou des mutants de ceux-ci sont envisagées.
MA39390A 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire MA39390B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21
PCT/US2015/021896 WO2015143418A2 (fr) 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire

Publications (2)

Publication Number Publication Date
MA39390A1 true MA39390A1 (fr) 2017-12-29
MA39390B2 MA39390B2 (fr) 2022-04-29

Family

ID=52829343

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39390A MA39390B2 (fr) 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire

Country Status (36)

Country Link
US (3) US10383953B2 (fr)
EP (3) EP3119437B1 (fr)
JP (3) JP6669664B2 (fr)
KR (2) KR20160127832A (fr)
CN (2) CN106456660B (fr)
AR (1) AR099837A1 (fr)
AU (1) AU2015230942B2 (fr)
CA (1) CA2943185A1 (fr)
CL (1) CL2016002333A1 (fr)
CR (1) CR20160480A (fr)
DK (2) DK3119437T3 (fr)
DO (1) DOP2016000237A (fr)
EA (1) EA201691891A1 (fr)
EC (1) ECSP16083000A (fr)
ES (2) ES2957840T3 (fr)
FI (1) FI3628334T3 (fr)
HR (2) HRP20231077T1 (fr)
HU (2) HUE046454T2 (fr)
IL (3) IL247543B (fr)
LT (2) LT3119437T (fr)
MA (1) MA39390B2 (fr)
MX (2) MX2016012201A (fr)
MY (1) MY190726A (fr)
NZ (1) NZ724622A (fr)
PE (1) PE20161252A1 (fr)
PH (1) PH12016501684A1 (fr)
PL (2) PL3628334T3 (fr)
PT (2) PT3628334T (fr)
RS (2) RS59634B1 (fr)
SG (3) SG11201607005UA (fr)
SI (2) SI3119437T1 (fr)
TW (2) TWI780401B (fr)
UA (1) UA120050C2 (fr)
UY (1) UY36044A (fr)
WO (1) WO2015143418A2 (fr)
ZA (1) ZA201605924B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120050C2 (uk) * 2014-03-21 2019-09-25 Джензайм Корпорейшн Генна терапія для лікування пігментного ретиніту
EP3256588A2 (fr) 2015-02-10 2017-12-20 Genzyme Corporation Variant d'arni
CN108474001B (zh) * 2015-12-03 2022-04-08 弗里德里克·米谢尔生物医学研究所 SynP160，用于基因在视杆光感受器中特异性表达的启动子
CN108472390B (zh) 2015-12-03 2022-04-15 弗里德里克·米谢尔生物医学研究所 SynP162,用于基因在视杆光感受器中特异性表达的启动子
JP6966442B2 (ja) * 2015-12-04 2021-11-17 ソルボンヌ・ユニヴェルシテSorbonne Universite プロモーター及びその使用
WO2017151823A1 (fr) * 2016-03-01 2017-09-08 University Of Florida Research Foundation, Inc. Vecteurs aav pour le traitement de la rétinite pigmentaire dominante
CN109890424A (zh) * 2016-07-05 2019-06-14 约翰霍普金斯大学 用于治疗视网膜变性的基于crispr/cas9的组合物和方法
US20200030458A1 (en) * 2017-03-21 2020-01-30 Stylianos Michalakis Gene Therapy for the Treatment of CNGB1-linked Retinitis Pigmentosa
CA3076191A1 (fr) * 2017-09-22 2019-03-28 Genzyme Corporation Variant d'arni
MX2020003351A (es) * 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Metodos, composiciones y elementos implantables que comprenden celulas activas.
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
EP3768327A4 (fr) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York Édition de gènes pour maladies autosomiques dominantes
WO2019232517A1 (fr) * 2018-06-01 2019-12-05 University Of Florida Research Foundation, Incorporated Compositions et méthodes pour le traitement de la rétinite pigmentaire dominante
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
SG11202109554XA (en) * 2019-03-04 2021-09-29 Univ Pennsylvania Neuroprotective gene therapy targeting the akt pathway
BR112021018354A2 (pt) * 2019-03-21 2021-11-23 Ptc Therapeutics Inc Vetor e método para tratar síndrome de angelman
KR102396200B1 (ko) * 2020-07-24 2022-05-12 알지노믹스 주식회사 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (fr) 1999-08-09 2013-03-26 Targeted Genetics Corporation Vecteurs viraux de recombinaison actives metaboliquement et procede de preparation et d'utilisation de ceux-ci
JP4860886B2 (ja) 2000-06-01 2012-01-25 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二本鎖パルボウイルスベクター
NZ600121A (en) 2001-11-13 2013-12-20 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
AU2005206410A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (fr) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, clonage, et caracterisation de nouveaux serotypes de virus adeno-associes (avv)
EP2007795B1 (fr) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Protéines de capsides aav
US8257969B2 (en) 2007-04-12 2012-09-04 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (fr) * 2009-05-28 2010-12-02 University Of Massachusetts Nouveaux virus adéno-associés (aav) et leurs utilisations
DK2475372T4 (da) * 2009-09-10 2020-11-30 Velin Pharma As Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
BR112012018899A2 (pt) 2010-01-28 2015-09-15 Philadelphia Children Hospital "método para purificar partículas de vetor de vírus adeno-associado."
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103189507A (zh) * 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经***细胞导入基因的腺相关病毒粒子
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
AU2013221212B2 (en) * 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
EP3501550A1 (fr) * 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Polynucléotides modifiés pour la production de protéines associées à une maladie humaine
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
GEP20217251B (en) 2012-05-25 2021-04-26 Charpentier Emmanuelle De Emanuel Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CN105120901A (zh) * 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
WO2014066498A1 (fr) * 2012-10-23 2014-05-01 Vivek Mittal Traitement du cancer du sein métastatique
TW201605470A (zh) 2013-10-04 2016-02-16 默沙東藥廠 葡萄糖反應性胰島素結合物
UA120050C2 (uk) 2014-03-21 2019-09-25 Джензайм Корпорейшн Генна терапія для лікування пігментного ретиніту

Also Published As

Publication number Publication date
AU2021200988A1 (en) 2021-03-11
US20170173183A1 (en) 2017-06-22
ZA201605924B (en) 2017-09-27
SI3628334T1 (sl) 2023-11-30
JP2017509632A (ja) 2017-04-06
IL284741B2 (en) 2023-02-01
RS59634B1 (sr) 2020-01-31
PE20161252A1 (es) 2016-11-30
EP3628334A1 (fr) 2020-04-01
IL284741A (en) 2021-08-31
LT3628334T (lt) 2023-09-25
JP7048563B2 (ja) 2022-04-05
DK3628334T3 (da) 2023-10-02
PT3119437T (pt) 2019-12-12
NZ762841A (en) 2023-11-24
AR099837A1 (es) 2016-08-24
WO2015143418A2 (fr) 2015-09-24
EP3119437A2 (fr) 2017-01-25
TW202021627A (zh) 2020-06-16
HUE046454T2 (hu) 2020-03-30
TW201622752A (zh) 2016-07-01
CN106456660B (zh) 2022-05-31
DK3119437T3 (da) 2019-12-09
US20200046851A1 (en) 2020-02-13
US10383953B2 (en) 2019-08-20
US11103598B2 (en) 2021-08-31
LT3119437T (lt) 2019-12-27
HRP20192141T1 (hr) 2020-02-21
ECSP16083000A (es) 2017-02-24
JP2020059737A (ja) 2020-04-16
SG11201607005UA (en) 2016-09-29
MY190726A (en) 2022-05-12
DOP2016000237A (es) 2016-10-16
TWI706789B (zh) 2020-10-11
TWI780401B (zh) 2022-10-11
JP2022084810A (ja) 2022-06-07
EA201691891A1 (ru) 2017-01-30
ES2760263T3 (es) 2020-05-13
BR112016021017A2 (pt) 2017-10-03
MX2016012201A (es) 2017-01-19
JP6669664B2 (ja) 2020-03-18
US20220054657A1 (en) 2022-02-24
CN106456660A (zh) 2017-02-22
CL2016002333A1 (es) 2017-05-26
FI3628334T3 (fi) 2023-09-15
NZ724622A (en) 2022-05-27
HRP20231077T1 (hr) 2023-12-22
KR20160127832A (ko) 2016-11-04
WO2015143418A3 (fr) 2015-11-19
MA39390B2 (fr) 2022-04-29
EP3628334B1 (fr) 2023-06-28
IL275918B (en) 2021-07-29
PH12016501684A1 (en) 2016-10-03
UA120050C2 (uk) 2019-09-25
PT3628334T (pt) 2023-09-26
RS64611B1 (sr) 2023-10-31
MX2020010694A (es) 2020-11-06
IL247543B (en) 2020-07-30
KR20230006039A (ko) 2023-01-10
IL275918A (en) 2020-08-31
UY36044A (es) 2015-10-30
HUE063460T2 (hu) 2024-01-28
AU2015230942A1 (en) 2016-10-13
CR20160480A (es) 2016-12-14
IL247543A0 (en) 2016-11-30
PL3628334T3 (pl) 2023-12-18
AU2015230942B2 (en) 2020-11-19
CA2943185A1 (fr) 2015-09-24
EP4345165A2 (fr) 2024-04-03
ES2957840T3 (es) 2024-01-26
SI3119437T1 (sl) 2020-01-31
CN115252823A (zh) 2022-11-01
PL3119437T3 (pl) 2020-04-30
IL284741B (en) 2022-10-01
SG10201912968WA (en) 2020-02-27
SG10201808218YA (en) 2018-10-30
EP3119437B1 (fr) 2019-09-04

Similar Documents

Publication Publication Date Title
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
CR20200196A (es) Proteínas trispecìficas y mètodos de uso
EA201790521A1 (ru) Направленная доставка лекарственных веществ, содержащих третичный амин
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX2019004280A (es) Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
ZA201701881B (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA201890543A1 (ru) Способы и материалы для генной терапии galgt2
MX2020010477A (es) Composiciones y metodos para el tratamiento de la distrofia macular.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA202192160A1 (ru) Доставка полинуклеотида cln3 с помощью аденоассоциированного вируса
EA202191115A1 (ru) Новые пиридазины
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2021008941A (es) Moduladores gpr35.
MX2022004836A (es) Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso.
EA202191927A1 (ru) Модуляторы gpr35
EA201992109A1 (ru) Способы лечения опосредованных комплементом заболеваний и расстройств
TN2019000238A1 (en) Methods for treating complement-mediated diseases and disorders
EA201990278A1 (ru) Модуляторы соматостатина и их применения
MA40818B2 (fr) Administration améliorée de particules virales au striatum et au cortex